MRVI (Maravai LifeSciences Holdings) Quality Rank

View and export this data going back to 2020. Start your Free Trial

What is Maravai LifeSciences Holdings Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:

Interest coverage
Zscore
Debt to revenue
Equity to asset
Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:

Operating margin mean rank (10-year mean average profit margine)
Operating margin growth rank
Fscore
Predictability rank
Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
Num of year profit (number of years that is profitable within the last 10 years)
ROIC median (10-year median of ROIC)

Maravai LifeSciences Holdings Quality Rank Related Terms

Thank you for viewing the detailed overview of Maravai LifeSciences Holdings's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Maravai LifeSciences Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Maravai LifeSciences Holdings Inc (NAS:MRVI) » Definitions » Quality Rank

Comparable Companies

Traded in Other Exchanges

MAR:Germany

Address

10770 Wateridge Circle, Suite 200, San Diego, CA, USA, 92121

Website

https://www.maravai.com

Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.

Executives

Kurt Oreshack	officer: General Counsel	10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
John A Deford	director	C R BARD INC, 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
Carl Hull	director, officer: Chief Executive Officer	300 N. LASALLE SUITE 5600, CHICAGO IL 60654
Gtcr Investment Xi Llc	director, 10 percent owner	300 NORTH LASALLE STREET, SUITE 5600, CHICAGO IL 60654
Rebecca Buzzeo	officer: See Remarks	C/O MARAVAI LIFESCIENCES HOLDINGS, INC., 10770 WATERIDGE CIRCLE, SUITE 200, SAN DIEGO CA 92121
Andrew Burch	officer: See Remarks	C/O MARAVAI LIFESCIENCES HOLDINGS, INC., 10770 WATERIDGE CIRCLE, SUITE 200, SAN DIEGO CA 92121
Martin William E. Iii	officer: See remarks	C/O MARAVAI LIFESCIENCES HOLDINGS, INC., 10770 WATERIDGE CIRCLE, SUITE 200, SAN DIEGO CA 92121
Peter Michael Leddy	officer: See Remarks	1620 FARADAY AVE, CARLSBAD CA 92008
Gregory T Lucier	director	C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Murali Prahalad	director	10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Lisa Sellers	officer: See Remarks	10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Susannah Gray	director	10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Robert B Hance	director	300 N. LASALLE SUITE 5600, CHICAGO IL 60654
Jessica Hopfield	director	C/O 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Benjamin James Daverman	director	300 N. LASALLE SUITE 5600, CHICAGO IL 60654